...
首页> 外文期刊>Vojnosanitetski Pregled >Gelatinases A and B activities in the serum of patients with various coronary artery disease stages
【24h】

Gelatinases A and B activities in the serum of patients with various coronary artery disease stages

机译:冠心病不同阶段患者血清中的明胶酶A和B活性

获取原文

摘要

Background/Aim. The main characteristic of matrix metalloproteinases (MMPs) is the degradation of extracellular matrix. Synthesis of MMPs has been reported in coronary atherosclerotic lesions in patients with coronary disease (CD) suggesting a pathogenic role of MMPs in its development. Recently there is increasing evidence that gelatinase A (pro MMP-2) and gelatinase B (proMMP-9) play a pathogenic role in the development of the atherosclerotic plaques. The aim of the study was to determine, by the use of a gel image system, a possible presence of active gelatinases in the serum of the patients with CD, as well as if their activity is higher in these patients than in healthy people. Methods. By gelatin zymography we analyzed the activity of proMMP-2 and proMMP-9 in the serum of 50 patients with various coronary artery disease stages and in the serum of 15 healthy controls. The activity was measured by using a gel image system (Kodak Image 1D 3.6.). Results. ProMMP-2 and proMMP-9 activity was significantly higher in the serum of patients with CD compared to controls. There was higher activity of MMP-2 and MMP-9 in the serum of patients with acute myocardial infarction (AMI) compared to patients with stable angina pectoris, as well as higher proMMP-9 activity in patients with unstable angina pectoris compared to patients with stable angina pectoris. Conclusion. ProMMP-2 and proMMP-9 participate in processes associated with destabilizing plaques and understanding the processes of MMPs activation and regulation may have significant benefits in clinical interpretation. The reported higher proMMP-2 and proMMP-9 activity in the serum of patients with CD suggests a role of proMMP-2 and proMMP-9 in prognostic stratification of these patients and in designing new drugs.
机译:背景/目标。基质金属蛋白酶(MMPs)的主要特征是细胞外基质的降解。在患有冠心病(CD)的患者的冠状动脉粥样硬化病变中已经报道了MMP的合成,这暗示了MMP在其发展中的致病作用。最近,越来越多的证据表明,明胶酶A(pro MMP-2)和明胶酶B(proMMP-9)在动脉粥样硬化斑块的形成中起致病作用。该研究的目的是通过使用凝胶成像系统来确定CD患者的血清中是否存在活性明胶酶,以及这些患者的活性是否比健康人高。方法。通过明胶酶谱分析,我们分析了50例患有各种冠心病的患者的血清和15例健康对照者血清中的proMMP-2和proMMP-9活性。通过使用凝胶图像系统(Kodak Image 1D 3.6。)测量活性。结果。与对照组相比,CD患者血清中的ProMMP-2和proMMP-9活性明显更高。与稳定型心绞痛患者相比,急性心肌梗死(AMI)患者血清中的MMP-2和MMP-9活性更高,而不稳定型心绞痛患者中proMMP-9活性更高。稳定型心绞痛。结论。 ProMMP-2和proMMP-9参与了与不稳定斑块相关的过程,并且了解MMPs激活和调节过程可能在临床解释中具有重大益处。据报道,CD患者血清中的proMMP-2和proMMP-9活性较高,表明proMMP-2和proMMP-9在这些患​​者的预后分层和设计新药物中具有作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号